Identification of Rab7 as an autophagy marker: potential therapeutic approaches and the effect of Qi Teng Xiao Zhuo granule in chronic glomerulonephritis

Pharm Biol. 2023 Dec;61(1):1120-1134. doi: 10.1080/13880209.2023.2233998.

Abstract

Context: Qi Teng Xiao Zhuo granule (QTXZG) is a traditional Chinese medicine (TCM) used for therapeutic effects on chronic glomerulonephritis (CGN). However, the underlying mechanism remains unclear.

Objective: To investigate the molecular mechanism of QTXZG on CGN by proteomics.

Materials and methods: The CGN model was induced in Sprague-Dawley rats by injecting adriamycin (3.5 mg/kg, Day 1; 3.0 mg/kg, Day 14) twice through the tail vein. Urine samples were collected on the 21st day; and the rats divided randomly into control, adriamycin, QTXZG administration groups. Rats in the QTXZG group received QTXZG (10.8 g/kg); control and adriamycin groups were given physiological saline once per day for 30 days. Proteomics was applied to identify the candidate proteins combined with autophagy database and verified by immunofluorescence (IF) and western blots (WB).

Results: 278 differentially expressed proteins (DEPs) were identified based on proteomics and Rab7 was screened as an autophagy protein biomarker. In vitro cell experiments, we found that QTXZG (20%, IC50 = 23.47%) could decrease the expression of NLRP3, Caspase-1, IL-18, IL-1β, while increasing the expression of Pink1, Parkin, Rab7, Podocalyxin. The cell apoptosis rate increased from 6.68 ± 0.07 to 11.03 ± 0.36%. Overexpression of Rab7 resulted in an increase in autophagy relevant protein expression.

Discussion and conclusion: TCM CGN-regulating herbs (QTXZG) can exert therapeutic effects by affecting the Rab7/Pink1/Parkin pathway to promote mitochondrial autophagy. New breakthroughs in targeted Rab7 may eventually enable such applications.

Keywords: DEPs; Proteomics; TCM; mechanisms; mitophagy.

MeSH terms

  • Animals
  • Autophagy
  • Chronic Disease
  • Doxorubicin / pharmacology
  • Doxorubicin / therapeutic use
  • Glomerulonephritis* / drug therapy
  • Protein Kinases / metabolism
  • Rats
  • Rats, Sprague-Dawley
  • Ubiquitin-Protein Ligases / metabolism
  • Ubiquitin-Protein Ligases / pharmacology
  • Ubiquitin-Protein Ligases / therapeutic use

Substances

  • Ubiquitin-Protein Ligases
  • Protein Kinases
  • Doxorubicin

Grants and funding

This work was supported by the [Natural Science Foundation of Anhui Province] under Grant [number 1908085QH343]; [National Natural Science Foundation of China] under Grant [number 82104613]; [Postgraduate scientific research project of Anhui University] under Grant [number YJS20210489]; and [Clinical Scientific Research Project of the First Affiliated Hospital of Anhui University of Chinese Medicine] under Grant [number 2020yfyzc03].